DouglasASimonettoMD(He/Him)

Hepatology & Liver Transplantation

Associate Professor of Medicine

Dr. Simonetto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Transplant Hepatology, 2015 - 2016
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2012 - 2015
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
Hlth Scis Fed Univ Porto AlegreClass of 2007

PubMed

2 citations
Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol-Associated Hepatitis: A Global Cohort Study.
Francisco Idalsoaga, Luis Antonio Díaz, Leonardo Guizzetti, Winston Dunn, Heer Mehta
Alimentary Pharmacology & Therapeutics. 2025-04-01
Moderate alcohol-associated hepatitis: A real-world multicenter study.
Francisco Idalsoaga, Luis Antonio Díaz, Winston Dunn, Heer Mehta, Karen Muñoz
Hepatology Communications. 2025-04-01
1 citations
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone.
Kavish R Patidar, Wanzhu Tu, Thomas G Cotter, Douglas A Simonetto, Amon Asgharpour
Hepatology. 2025-04-01

Journal Articles

Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta‐Analysis
Douglas A Simonetto, Mohammad Hassan Murad, Siddharth Singh, Patrick S Kamath, Hepatology

Abstracts/Posters

Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes
Douglas A Simonetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024
PharmaIN to Present Promising Interim Data from Its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at the Liver Meeting® 2024October 16th, 2024
Surge in Alcohol-Related Disease During Pandemic Reveals Unmet Need for TreatmentMay 31st, 2022
Join now to see all

Liver Cirrhosis Network: Clinical Research Center - Mayo ClinicMAYO CLINIC ROCHESTER2021–2026
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic HepatitisMAYO CLINIC ROCHESTER2018–2024